<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03542903</url>
  </required_header>
  <id_info>
    <org_study_id>2017-A02657-46</org_study_id>
    <nct_id>NCT03542903</nct_id>
  </id_info>
  <brief_title>ECT in Ultra-resistant Schizophrenia</brief_title>
  <acronym>SURECT</acronym>
  <official_title>Clinical Trial Comparing Two Electroconvulsive Therapy (ECT) Application Schemas in Ultra-resistant Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier du Rouvray</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Henri Laborit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier St Anne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier de Cadillac</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>HÃ´pital Louis Mourier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre hospitalier de Ville-Evrard, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier du Rouvray</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effects of the ECT in schizophrenia ultra-resistant were studied in short times (4-6&#xD;
      months in most studies with follow-up). The literature identified a high relapse rate of 32%&#xD;
      in the weeks to months after ECT discontinuation. The use of the ECT in the prevention of the&#xD;
      relapse is partially known. In an empirical way, experts recommend protocols of prevention of&#xD;
      the relapse going from 6 to 12 months. Nevertheless, the profit of a long cure (12 months)&#xD;
      compared with a short cure (6 months) was never determined. Therefore, the investigators&#xD;
      decided to lead a prospective randomized controlled study in order to compare the response&#xD;
      rates between the two strategies of clozapine and ECT combinations applied to URS patients.&#xD;
      The treatment consisted either in a short therapy of six months or a longer course of therapy&#xD;
      of twelve months. To the investigators' knowledge, it is the first study which compares two&#xD;
      ECT strategies (both the short duration and the longer one) for the treatment of URS&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 4, 2018</start_date>
  <completion_date type="Anticipated">October 4, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 4, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A multicentric, prospective, random-assignment study incorporating both non-blinded treatment and blinded assessment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>non-blinded treatment and blinded assessment</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The response rate (a 30% decrease in the Positive and Negative Syndrome Scale (PANSS)) at 15th month</measure>
    <time_frame>three months after the end of the treatment (i.e. 9 and 15 months)</time_frame>
    <description>The response rate (a 30% decrease in the PANSS, ranging from 30, the minimum, to 210, the most severe score) at 15th month</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The response rate (a 30% decrease in the Brief Psychiatric Rating Scale (BPRS))</measure>
    <time_frame>three months after the end of the treatment (i.e. 9 and 15 months)</time_frame>
    <description>The response rate (a 30% decrease in the BPRS, ranging from 18, the minimum, to 126, the most severe score) at 15th month.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The response rate (a 30% decrease in the BPRS) at different times of the study</measure>
    <time_frame>2, 4, 6 and 12 months</time_frame>
    <description>The response rate (a 30 % decrease in the BPRS) at 2, 4, 6 and 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate (a 30% decrease in the PANSS) at different times of the study</measure>
    <time_frame>2, 4, 6 and 12 months</time_frame>
    <description>The response rate (a 30 % decrease in the PANSS) at 2, 4, 6 and 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological assessment- MMSE</measure>
    <time_frame>-1, 6 and 15 months</time_frame>
    <description>The scores and variations of the Mini Mental Status Examination (MMSE) at -1, 6 and 15 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological assessment- SSTICS</measure>
    <time_frame>-1, 6 and 15 months</time_frame>
    <description>The scores and variations of the Subjective Scale To Investigate Cognition In Schizophrenia (SSTICS, scores ranging from 0 to 84, the most severe score) at -1, 6 and 15 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological assessment- Grober and Buschke test</measure>
    <time_frame>-1, 6 and 15 months</time_frame>
    <description>The scores and variations of the test of Grober and Buschke at -1, 6 and 15 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological assessment- test of doors</measure>
    <time_frame>-1, 6 and 15 months</time_frame>
    <description>The scores and variations of the test of doors at -1, 6 and 15 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological assessment- test of d2</measure>
    <time_frame>-1, 6 and 15 months</time_frame>
    <description>The scores and variations of the test of d2 at -1, 6 and 15 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological assessment - &quot;figure de Rey&quot; test</measure>
    <time_frame>-1, 6 and 15 months</time_frame>
    <description>the scores ans variations of the test of &quot; figure de Rey&quot; at -1, 6 and 15 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other clinical assessment- HAMD-21</measure>
    <time_frame>day 1 and 2, 4, 6, 9, 12 and 15 months</time_frame>
    <description>The scores and variations of the Hamilton Rating Scale-21 items (HAMD-21, scores ranging from 0 to 64, the most severe score) at day 1 and 2, 4, 6, 9, 12 and 15 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other clinical assessment-YMRS</measure>
    <time_frame>day 1 and 2, 4, 6, 9, 12 and 15 months</time_frame>
    <description>The scores and variations of the Young Mania Rating Scale (YMRS, scores ranging from 0 to 60, the most severe score) at day 1 and 2, 4, 6, 9, 12 and 15 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other clinical assessment-GAF</measure>
    <time_frame>day 1 and 2, 4, 6, 9, 12 and 15 months</time_frame>
    <description>The scores and variations of the Global Assessment Functioning (GAF, scores ranging from 0 to 100, the best score) at day 1 and 2, 4, 6, 9, 12 and 15 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other clinical assessment-MOAS</measure>
    <time_frame>day 1 and 2, 4, 6, 9, 12 and 15 months</time_frame>
    <description>The scores and variations of the Modified Overt Aggression Scale (MOAS, scores ranging from 0 to 100, the most severe score) at day 1 and 2, 4, 6, 9, 12 and 15 months.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Electroconvulsive Therapy</condition>
  <arm_group>
    <arm_group_label>Short ECT arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the short arm, bitemporal ECT is administered twice a week during the first 6 weeks. Afterwards, it is administered once a week during 4 weeks. After that, the patients will have one ECT every 3 weeks during 6 weeks. Lastly, patients will receive one ECT each month during 2 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Long ECT arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the long arm, bitemporal ECT is administered twice a week during the first 12 weeks. Afterwards, it is administered once a week during 8 weeks. After that, the patients will have one ECT every 3 weeks during 12 weeks. Lastly, patients will receive one ECT each month during 4 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Electroconvulsive therapy</intervention_name>
    <description>Electroconvulsive therapy is administered through electrodes positioned bilaterally (for quicker efficacy) on the frontotemporal region.&#xD;
The stimulation dose is determined by titration method, during the first ECT session.&#xD;
The dose for therapeutic stimulation will be twice the seizure threshold. This dose may be increased as the crisis does not meet the effectiveness criteria, as is recommended.&#xD;
For patients undergoing ECT, an intravenous injection of etomidate (between 0.1 and 0.7 mg/kg) and suxamethonium chloride (0.8 and 1.2 mg/kg) is performed. The required doses are adapted according to each patient by the anaesthetist and they are documented in the patients' files. A mixture of etomidate and propofol can be used in second-line or just propofol in third-line (no more than 2mg/kg).</description>
    <arm_group_label>Long ECT arm</arm_group_label>
    <arm_group_label>Short ECT arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with URS: patients who continue to experience persistent positive psychotic&#xD;
             symptoms: item score of 4 (moderate) on at least two of four positive symptoms on the&#xD;
             BPRS (grandiosity, suspiciousness, hallucinations and unusual thoughts), current&#xD;
             presence of at least moderately severe illness on the total BPRS-18 (45) and a score&#xD;
             of 4 (moderate) on the CGI-S, despite a period of clozapine therapy of at least 6&#xD;
             weeks with a plasma concentration of 350 ng/ml and at least two unsuccessful previous&#xD;
             treatment trials with conventional or atypical antipsychotic drugs from two distinct&#xD;
             families at a dose 600 mg of chlorpromazine equivalents.&#xD;
&#xD;
          -  Age: from 18 to 55&#xD;
&#xD;
          -  Patients with stable treatments for at least 8 weeks (antipsychotics, mood stabilizers&#xD;
             and antidepressants).&#xD;
&#xD;
          -  Participants who gave their informed, written consents and agreement of their guardian&#xD;
             for the patients under guardianship&#xD;
&#xD;
          -  Patients deprived of liberty if they gave their informed, written consents&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current affective episode according to DSM-5 criteria;&#xD;
&#xD;
          -  ECT within (the last) 6 months;&#xD;
&#xD;
          -  Unstable epilepsy ; severe neurological or systemic disorder that could significantly&#xD;
             affect cognition, behavior, or mental status (other than late dyskinesia or&#xD;
             neuroleptic-induced parkinsonism);&#xD;
&#xD;
          -  Severe substance use disorders (other than nicotine or caffeine) according to DSM-5&#xD;
             criteria.&#xD;
&#xD;
          -  Concomitant use of antiepileptics and benzodiazepines apart from lamotrigine&#xD;
&#xD;
          -  Women of childbearing age with no adequate contraception, pregnant or lactating women;&#xD;
&#xD;
          -  Patients having contraindications to etomidate or any of its excipients;&#xD;
&#xD;
          -  Patients having contraindications to neuromuscular blocking agents;&#xD;
&#xD;
          -  Patients participating or having participated in an interventional clinical trial&#xD;
             within 30 days prior to the inclusion visit;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Maud RothÃ¤rmel, MD</last_name>
    <phone>0033232956825</phone>
    <email>maud.rotharmel@ch-lerouvray.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aline Augustynen</last_name>
    <phone>0033232956825</phone>
    <email>aline.augustynen@ch-lerouvray.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Charles Perrens</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clelia Quiles, Md,PhD</last_name>
    </contact>
    <investigator>
      <last_name>Clelia Quiles, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Cadillac</name>
      <address>
        <city>Cadillac</city>
        <zip>33410</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick Le Bihan, MD</last_name>
    </contact>
    <investigator>
      <last_name>Patrick Le Bihan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Caen</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierrick Lebain, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pierrick Lebain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>ClÃ©ment Nathou, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sonia Dollfus, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clermont-Ferrand Hospital</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-Michel Llorca, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montpellier University Hospital</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JerÃ´me Attal, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Sauvaget, MD,PhD</last_name>
    </contact>
    <investigator>
      <last_name>Anne Sauvaget, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Samuel Bulteau, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Marie Vanelle, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edouard Laforgue, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>EPS Ville Evrard</name>
      <address>
        <city>Neuilly-sur-Marne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dominique Januel, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Noomane Bouaziz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominique Januel, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Saint Anne</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Odile Krebs, MD,PhD</last_name>
    </contact>
    <investigator>
      <last_name>Marie-Odile Krebs, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marion Plaze, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Henri Laborit</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nemat Jaafari, MD,PhD</last_name>
    </contact>
    <investigator>
      <last_name>Nemat Jaafari, Md,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Arbus, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christophe Arbus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie Sporer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 11, 2018</study_first_submitted>
  <study_first_submitted_qc>May 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2018</study_first_posted>
  <last_update_submitted>September 15, 2020</last_update_submitted>
  <last_update_submitted_qc>September 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

